Using Second-Generation Anti-Obesity Medications.

Autor:	Schmitz, Sarah H., Aronne, Louis J.
Předmět:	OBESITY genetics WEIGHT loss NON-alcoholic fatty liver disease TYPE 1 diabetes BEHAVIOR modification PATIENT safety HYPOGLYCEMIC agents ORAL drug administration ANTIOBESITY agents DRUG efficacy HEALTH behavior TYPE 2 diabetes SLEEP apnea syndromes CHILDHOOD obesity SUBCUTANEOUS injections
Zdroj:	Diabetes Spectrum; Fall2024, Vol. 37 Issue 4, p303-312, 10p
Abstrakt:	Second-generation anti-obesity medications are more effective than their first-generation predecessors, resulting in an average weight loss of 15% when combined with lifestyle modifications. This article examines the efficacy and therapeutic implications of the three currently approved second-generation medications: setmelanotide for individuals with monogenic forms of obesity, semaglutide 2.4 mg, and tirzepatide. Particular emphasis is placed on the concurrent treatment of obesity and type 2 diabetes with semaglutide 2.4 mg and tirzepatide. [ABSTRACT FROM AUTHOR]
Databáze:	Complementary Index
Externí odkaz:	Zobrazit plný text záznamu